乾癬性関節炎と乾癬でトファシチニブ治療中の患者におけるベースライン心血管疾患リスクと主要心血管有害事象と悪性腫瘍罹患率の関連

Baseline 10-year atherosclerotic cardiovascular disease risk and metabolic syndrome are potentially associated with the incidence of both MACE and malignancies in patients receiving TOFA in the PsA and PsO clinical trial programs. This post hoc analysis aimed to examine the baseline CV disease risk and its association with the occurrence of MACE and malignancies in TOFA-treated patients with PsA and PsO.

These results confirm the importance of assessing CV risk and adequate prevention in patients with PsA and PsO and suggest enhanced cancer monitoring in patients with significant 10-year ASCVD risk.